Secukinumab is superior to Fumaric Acid Esters in the Treatment of Patients with moderate to severe Plaque Psoriasis without previous Systemic Therapy for Improvement of Skin Symptoms: PASI and IGA mod. 2011-Results of the PRIME Study

Reich K, Mrowietz U, Augustin M, Thaci D, Kneidl J, Hentschke C, Simang M, Sieder C, Melzer N, Sticherling M (2017)

Publication Type: Conference contribution

Publication year: 2017

Journal

Journal der Deutschen Dermatologischen Gesellschaft Wiley-Blackwell

Book Volume: 15

Pages Range: 143-144

Authors with CRIS profile

Michael Sticherling Professur für Dermatologie

Involved external institutions

Universitätsklinikum Schleswig-Holstein (UKSH) DE Germany (DE) Novartis AG CH Switzerland (CH) Dermatologikum Hamburg DE Germany (DE) Universitätsklinikum Hamburg-Eppendorf (UKE) DE Germany (DE)

How to cite

APA:

Reich, K., Mrowietz, U., Augustin, M., Thaci, D., Kneidl, J., Hentschke, C.,... Sticherling, M. (2017). Secukinumab is superior to Fumaric Acid Esters in the Treatment of Patients with moderate to severe Plaque Psoriasis without previous Systemic Therapy for Improvement of Skin Symptoms: PASI and IGA mod. 2011-Results of the PRIME Study. (pp. 143-144).

MLA:

Reich, K., et al. "Secukinumab is superior to Fumaric Acid Esters in the Treatment of Patients with moderate to severe Plaque Psoriasis without previous Systemic Therapy for Improvement of Skin Symptoms: PASI and IGA mod. 2011-Results of the PRIME Study." 2017. 143-144.

BibTeX: Download